Our findings underscore the significant burden of AKI in this vulnerable patient population, with an incidence of 31.8%, and highlight the potential utility of novel biomarkers such as cystatin C and NGAL, as well as clinical parameters like intraoperative hematocrit levels, for early risk stratification and management. This evidence concerns the gene LCN2 and acute kidney injury.